Shuwen Qian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shuwen Qian has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Lijun Liao
Department of Pain Management, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China
4 shared publications - Chunzheng Liu
Department of Pain Management, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China
2 shared publications - Jiaqi Lin
Department of Pain Management, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China
2 shared publications - Jinyuan Zhang
Department of Pain Management, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China
2 shared publications Qianhao Hou
Department of Pain Management, School of Medicine, Shanghai East Hospital, Tongji University, Shanghai, China
2 shared publications- Qianhao Hou
Department of Pain Management, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China
2 shared publications
Latest Publications
- Open Access
- 17 September 2025
- Published by Microbiology Society in Journal of Medical Microbiology
- Vol. 74 (9) , 002038
Ozone water enema activates SIRT1-Nrf2/HO-1 pathway to ameliorate gut dysbiosis in mice receiving COVID-19 patient-derived faecal microbiota
Introduction. This study centres on how coronavirus disease 2019 (COVID-19) disrupts the intestinal microbiota and amplifies systemic inflammation and evaluates ozone water enemas as a strategy to restore gut microbial balance and activate the SIRT1 (silent information regulator of transcription 1)-Nrf2 (nuclear factor erythroid 2-related factor 2)/HO-1 (heme oxygenase-1) pathway for alleviating post-viral sequelae. Our findings demonstrate that ozone water intervention markedly improves the intestinal microenvironment in mice receiving COVID-19 patient-derived microbiota and attenuates systemic inflammation, offering a viable adjunctive approach for COVID-19 management. Hypothesis. Despite significant progress in reducing the incidence of COVID-19, its long-term consequences, including hepatic dysfunction, pulmonary injury and gut microbiota dysbiosis, remain challenging. While ozonated water enema therapy has shown efficacy in alleviating inflammation and neutralizing oxidative stress, the precise mechanisms by which ozonated water attenuates COVID-19 progression are not fully understood. We hypothesized that ozonated water enemas could enrich gut microbiota composition in COVID-19 patients, thereby optimizing the gut environment following faecal transplantation in a murine model. Aim. The overarching aim of this investigation was to ascertain whether ozonated water enemas could exert a salutogenic effect on the gut microbiota in a mouse model, as well as on the holistic gut and systemic health of critically ill COVID-19 patients subsequent to faecal transplantation. Methodology. The entire experiment was conducted over a 14-day period. WT mice were randomly allocated into three groups: Sham, FMT (faecal microbiota transplantation) and FMT+O3 (FMT with ozonewater enema treatment). Mid-stage faecal specimens were collected from 21 severe COVID-19 patients and randomly divided into seven subgroups (three specimens per subgroup). These specimens were transplanted into the WT mice of the FMT and FMT+O3 groups via faecal gavage on days 1 through 7. The healthy control group (Sham) received oral administration of ddH₂O instead. Starting on day 8 post-transplantation, the FMT+O3 group underwent ozone water enema treatment for seven consecutive days. During this treatment period, assessments were performed to evaluate intestinal barrier function, inflammatory changes and alterations in gut microbiota. Additionally, improvements in intestinal, hepatic, pulmonary and systemic lesions were examined. Results. Our findings indicate that ozonated water enemas modulate the SIRT1-Nrf2/HO-1 pathway, significantly enhancing the intestinal environment in mice that received FMT from COVID-19 patients. This intervention increased microbiota populations, strengthened intestinal barrier integrity and reduced intestinal and systemic inflammatory responses. Conclusion. The results highlight the potential of ozonated water enemas as a therapeutic option for COVID-19 patients, particularly in optimizing intestinal microbiota and mitigating inflammatory responses through SIRT1-Nrf2/HO-1 pathway modulation. This approach offers a novel strategy for addressing residual effects of COVID-19.
- 17 September 2025
- Published by Microbiology Society in Journal of Medical Microbiology
- Vol. 74 (9) , 002038
Open AccessOzone water enema activates SIRT1-Nrf2/HO-1 pathway to ameliorate gut dysbiosis in mice receiving COVID-19 patient-derived faecal microbiota
Introduction. This study centres on how coronavirus disease 2019 (COVID-19) disrupts the intestinal microbiota and amplifies systemic inflammation and evaluates ozone water enemas as a strategy to restore gut microbial balance and activate the SIRT1 (silent information regulator of transcription 1)-Nrf2 (nuclear factor erythroid 2-related factor 2)/HO-1 (heme oxygenase-1) pathway for alleviating post-viral sequelae. Our findings demonstrate that ozone water intervention markedly improves the intestinal microenvironment in mice receiving COVID-19 patient-derived microbiota and attenuates systemic inflammation, offering a viable adjunctive approach for COVID-19 management. Hypothesis. Despite significant progress in reducing the incidence of COVID-19, its long-term consequences, including hepatic dysfunction, pulmonary injury and gut microbiota dysbiosis, remain challenging. While ozonated water enema therapy has shown efficacy in alleviating inflammation and neutralizing oxidative stress, the precise mechanisms by which ozonated water attenuates COVID-19 progression are not fully understood. We hypothesized that ozonated water enemas could enrich gut microbiota composition in COVID-19 patients, thereby optimizing the gut environment following faecal transplantation in a murine model. Aim. The overarching aim of this investigation was to ascertain whether ozonated water enemas could exert a salutogenic effect on the gut microbiota in a mouse model, as well as on the holistic gut and systemic health of critically ill COVID-19 patients subsequent to faecal transplantation. Methodology. The entire experiment was conducted over a 14-day period. WT mice were randomly allocated into three groups: Sham, FMT (faecal microbiota transplantation) and FMT+O3 (FMT with ozonewater enema treatment). Mid-stage faecal specimens were collected from 21 severe COVID-19 patients and randomly divided into seven subgroups (three specimens per subgroup). These specimens were transplanted into the WT mice of the FMT and FMT+O3 groups via faecal gavage on days 1 through 7. The healthy control group (Sham) received oral administration of ddH₂O instead. Starting on day 8 post-transplantation, the FMT+O3 group underwent ozone water enema treatment for seven consecutive days. During this treatment period, assessments were performed to evaluate intestinal barrier function, inflammatory changes and alterations in gut microbiota. Additionally, improvements in intestinal, hepatic, pulmonary and systemic lesions were examined. Results. Our findings indicate that ozonated water enemas modulate the SIRT1-Nrf2/HO-1 pathway, significantly enhancing the intestinal environment in mice that received FMT from COVID-19 patients. This intervention increased microbiota populations, strengthened intestinal barrier integrity and reduced intestinal and systemic inflammatory responses. Conclusion. The results highlight the potential of ozonated water enemas as a therapeutic option for COVID-19 patients, particularly in optimizing intestinal microbiota and mitigating inflammatory responses through SIRT1-Nrf2/HO-1 pathway modulation. This approach offers a novel strategy for addressing residual effects of COVID-19.
- Open Access
- 15 July 2025
- Published by Elsevier in Journal of Advanced Research
- Vol. 82, 881-900
Hyodeoxycholic acid relieves neuropathic pain by activating farnesoid X receptor signaling
- 15 July 2025
- Published by Elsevier in Journal of Advanced Research
- Vol. 82, 881-900
Open AccessHyodeoxycholic acid relieves neuropathic pain by activating farnesoid X receptor signaling
- Open Access
- 21 May 2025
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 23 (1) , 1-25
Inhibition of Farnesoid-x-receptor signaling during abdominal sepsis by dysbiosis exacerbates gut barrier dysfunction
Bacterial translocation and intestinal dysbiosis due to gut barrier dysfunction are widely recognized as major causes of the initiation and development of intra-abdominal sepsis. Systemic bacterial translocation and hepatic activation of the myeloid differentiation primary response gene 88 (Myd88) can disturb bile acids (BAs) metabolism, further exacerbating intestinal dysbiosis. The farnesoid X receptor (FXR) and fibroblast growth factor (FGF) 15/19 are well known to be involved in the control of BAs synthesis and enterohepatic circulation. However, the influence of intestinal microbiota on intestinal Myd88 signaling, the FXR/FGF15 axis, as well as gut-liver crosstalk during sepsis remains unclear. The present study aims to decipher the role of intestinal Myd88 in abdominal sepsis, its impact on intestinal FXR signaling and FGF15-mediated gut-liver crosstalk. Expression levels of FXR and FGF15 in the liver and intestines, alongside assessments of gut barrier function, were evaluated in septic wild-type (WT) mice 24 h post-cecal ligation and puncture (CLP) surgery. Subsequently, the FXR agonist INT-747 was administered to explore the relationship between FXR activation and gut barrier function. Further investigations involved Myd88-deficient mice with specific deletion of Myd88 in intestinal epithelial cells (Myd88△IEC), subjected to CLP to examine the interplay among intestinal Myd88, FXR, gut barrier function, microbiota, and BA composition. Additionally, fecal microbiota transplantation (FMT) from septic mice to Myd88△IEC mice was conducted to study the impact of dysbiosis on intestinal Myd88 expression during sepsis, using floxed (Myd88fl/fl) mice as controls. Finally, the effects of the probiotic intervention on gut barrier function and sepsis outcomes in CLP mice were investigated. Induction of sepsis via CLP led to hepatic cholestasis, suppressed FXR-FGF15 signaling, altered gut microbiota composition, and compromised gut barrier function. Administration of INT-747 increased intestinal FXR and FGF15 expression, strengthened gut barrier function, and enhanced barrier integrity. Interestingly, Myd88△IEC mice exhibited partial reversal of sepsis-induced changes in FXR signaling, BA metabolism, and intestinal function, suggesting enhanced FXR expression upon Myd88 knockdown. Moreover, FMT from septic mice activated intestinal Myd88, subsequently suppressing FXR-FGF15 signaling, exacerbating cholestasis, and ultimately compromising gut barrier function. Probiotic treatment during abdominal sepsis mitigated flora disturbances, reduced Myd88 activation in the intestinal epithelium, increased FXR expression, alleviated cholestasis, and consequently reduced barrier damage. This study highlights the critical role of Myd88/FXR signaling in intestinal epithelial cells as a pivotal mediator of the detrimental effects induced by sepsis-related intestinal dysbiosis on barrier function and bile acid metabolism. In summary, disordered intestinal flora in septic mice specifically triggers intestinal epithelial Myd88 activation, inhibit the FXR-FGF15 axis, and then worsen intestinal barrier function impairment.
- 21 May 2025
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 23 (1) , 1-25
Open AccessInhibition of Farnesoid-x-receptor signaling during abdominal sepsis by dysbiosis exacerbates gut barrier dysfunction
Bacterial translocation and intestinal dysbiosis due to gut barrier dysfunction are widely recognized as major causes of the initiation and development of intra-abdominal sepsis. Systemic bacterial translocation and hepatic activation of the myeloid differentiation primary response gene 88 (Myd88) can disturb bile acids (BAs) metabolism, further exacerbating intestinal dysbiosis. The farnesoid X receptor (FXR) and fibroblast growth factor (FGF) 15/19 are well known to be involved in the control of BAs synthesis and enterohepatic circulation. However, the influence of intestinal microbiota on intestinal Myd88 signaling, the FXR/FGF15 axis, as well as gut-liver crosstalk during sepsis remains unclear. The present study aims to decipher the role of intestinal Myd88 in abdominal sepsis, its impact on intestinal FXR signaling and FGF15-mediated gut-liver crosstalk. Expression levels of FXR and FGF15 in the liver and intestines, alongside assessments of gut barrier function, were evaluated in septic wild-type (WT) mice 24 h post-cecal ligation and puncture (CLP) surgery. Subsequently, the FXR agonist INT-747 was administered to explore the relationship between FXR activation and gut barrier function. Further investigations involved Myd88-deficient mice with specific deletion of Myd88 in intestinal epithelial cells (Myd88△IEC), subjected to CLP to examine the interplay among intestinal Myd88, FXR, gut barrier function, microbiota, and BA composition. Additionally, fecal microbiota transplantation (FMT) from septic mice to Myd88△IEC mice was conducted to study the impact of dysbiosis on intestinal Myd88 expression during sepsis, using floxed (Myd88fl/fl) mice as controls. Finally, the effects of the probiotic intervention on gut barrier function and sepsis outcomes in CLP mice were investigated. Induction of sepsis via CLP led to hepatic cholestasis, suppressed FXR-FGF15 signaling, altered gut microbiota composition, and compromised gut barrier function. Administration of INT-747 increased intestinal FXR and FGF15 expression, strengthened gut barrier function, and enhanced barrier integrity. Interestingly, Myd88△IEC mice exhibited partial reversal of sepsis-induced changes in FXR signaling, BA metabolism, and intestinal function, suggesting enhanced FXR expression upon Myd88 knockdown. Moreover, FMT from septic mice activated intestinal Myd88, subsequently suppressing FXR-FGF15 signaling, exacerbating cholestasis, and ultimately compromising gut barrier function. Probiotic treatment during abdominal sepsis mitigated flora disturbances, reduced Myd88 activation in the intestinal epithelium, increased FXR expression, alleviated cholestasis, and consequently reduced barrier damage. This study highlights the critical role of Myd88/FXR signaling in intestinal epithelial cells as a pivotal mediator of the detrimental effects induced by sepsis-related intestinal dysbiosis on barrier function and bile acid metabolism. In summary, disordered intestinal flora in septic mice specifically triggers intestinal epithelial Myd88 activation, inhibit the FXR-FGF15 axis, and then worsen intestinal barrier function impairment.
- Open Access
- 20 November 2024
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 11, 1434767
The efficacy and safety of remimazolam in painless colonoscopy: a prospective, randomized clinical trial
Purpose: Remimazolam is a new type of ultra-short-effect intravenous anesthetic, that may provide adequate sedation for endoscopy while causing less cardiovascular or respiratory disturbance than propofol. The aim of this clinical study was to compare the efficacy and safety of two different doses of remimazolam with propofol for sedation during colonoscopy.Patients and methods: 225 subjects, aged 18 to 80 years, with American Society of Anesthesiology physical status I-III, were scheduled to undergo colonoscopy. All the subjects were randomly assigned to three groups, Low-Rem group (low dose remimazolam, 0.15 mg/kg, iv, n = 75), High-Rem group (high dose remimazolam, 0.2 mg/kg, iv, n = 75), and Propofol group (propofol 2 mg/kg, iv, n = 75). Every individual in this trial was given nalbuphine hydrochloride (0.2 mg/kg, iv) before administration of remimazolam or propofol. The primary outcome was the success rate of sedation. Haemodynamic parameters and adverse events were recorded to evaluate safety. Satisfaction of sedation from patients, anesthesiologists and gastroenterologists were also recorded.Results: The success rate of colonoscopy procedure was 100% in both High-Rem and Propofol groups, but it was 89% in Low-Rem group (p < 0.05). Furthermore, the induction time of anesthesia was shorter in Propofol group, when compared to the Low-Rem group and the High-Rem group (p < 0.05). The recovery time in Low-Rem group, High-Rem group, and Propofol group was 2.33, 2.43, and 3.21 min (p < 0.05) respectively, and the time of discharge was 25.00, 25.01, and 27.56 min (p < 0.05) respectively. Simultaneously, the incidence of adverse events such as hypotension, bradycardia, and respiratory depression in the remimazolam groups were significantly lower than that in the propofol group. No significant differences were observed among the three groups in Ramsay scale, BPS-NI scale, and Limb movement classification. Moreover, patients, anesthesiologists, and gastroenterologists were all satisfied with the sedation process.Conclusion: Remimazolam can be used safely and effectively for colonoscopy. 0.2 mg/kg remimazolam and propofol have the same sedation success rate and more stable hemodynamics and fewer side effects than propofol.Clinical trial registration: ChiCTR2100054053.
- 20 November 2024
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 11, 1434767
Open AccessThe efficacy and safety of remimazolam in painless colonoscopy: a prospective, randomized clinical trial
Purpose: Remimazolam is a new type of ultra-short-effect intravenous anesthetic, that may provide adequate sedation for endoscopy while causing less cardiovascular or respiratory disturbance than propofol. The aim of this clinical study was to compare the efficacy and safety of two different doses of remimazolam with propofol for sedation during colonoscopy.Patients and methods: 225 subjects, aged 18 to 80 years, with American Society of Anesthesiology physical status I-III, were scheduled to undergo colonoscopy. All the subjects were randomly assigned to three groups, Low-Rem group (low dose remimazolam, 0.15 mg/kg, iv, n = 75), High-Rem group (high dose remimazolam, 0.2 mg/kg, iv, n = 75), and Propofol group (propofol 2 mg/kg, iv, n = 75). Every individual in this trial was given nalbuphine hydrochloride (0.2 mg/kg, iv) before administration of remimazolam or propofol. The primary outcome was the success rate of sedation. Haemodynamic parameters and adverse events were recorded to evaluate safety. Satisfaction of sedation from patients, anesthesiologists and gastroenterologists were also recorded.Results: The success rate of colonoscopy procedure was 100% in both High-Rem and Propofol groups, but it was 89% in Low-Rem group (p < 0.05). Furthermore, the induction time of anesthesia was shorter in Propofol group, when compared to the Low-Rem group and the High-Rem group (p < 0.05). The recovery time in Low-Rem group, High-Rem group, and Propofol group was 2.33, 2.43, and 3.21 min (p < 0.05) respectively, and the time of discharge was 25.00, 25.01, and 27.56 min (p < 0.05) respectively. Simultaneously, the incidence of adverse events such as hypotension, bradycardia, and respiratory depression in the remimazolam groups were significantly lower than that in the propofol group. No significant differences were observed among the three groups in Ramsay scale, BPS-NI scale, and Limb movement classification. Moreover, patients, anesthesiologists, and gastroenterologists were all satisfied with the sedation process.Conclusion: Remimazolam can be used safely and effectively for colonoscopy. 0.2 mg/kg remimazolam and propofol have the same sedation success rate and more stable hemodynamics and fewer side effects than propofol.Clinical trial registration: ChiCTR2100054053.